The report forecasts the global metabolic disorders therapeutics market to grow at a CAGR of 4.62% during the period 2016-2020.
Strategic collaborations and acquisitions will be a key trend for market growth. M&A are usually intended to enhance a company's product portfolio and increase the acquiring company's market penetration. Established pharmaceutical companies acquire late-stage products from small companies, where the product's efficacy has already been demonstrated, cutting down on initial R&D expenditure. Joint ventures between different companies enable the use of technical expertise from both companies for mutual benefits, allowing the use of regulatory and developmental experience gained by one company to support the pipeline candidates of the other. It also ensures the in-flow of adequate funds for R&D.
According to the report, increase in academia-industry collaborations for drug development will be a key driver for market growth. The key players in the global diabetes therapeutics market are increasingly extending their support to academic institutions to facilitate the R&D of innovative products for the treatment of diabetes. Such collaborations enable the amalgamation of research expertise of educational institutions with the marketing intelligence of pharma companies, as well as provides funds for conducting trials.
Further, the report states that low compliance and adherence rates will be a challenge for the market. Despite the availability of various treatment options for metabolic disorders, there exist significant unmet medical needs because of the presence of adverse effects with the existing treatment options. Most of the therapies used for metabolic disorders should be continued on a long-term basis. Adverse effects lead to low compliance and adherence rates for these therapies. Also, the availability of alternative treatment options will discourage compliance.
- Novo Nordisk
- Eli Lilly
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Pipeline portfolio
PART 06: Market landscape
PART 07: Market segmentation by type of disease
PART 08: Global diabetes drugs market
PART 09: Global hypercholesterolemia drugs market
PART 10: Global lysosomal storage diseases market
PART 11: Global anti-obesity drugs market
PART 12: Geographical segmentation
PART 13: Market drivers
PART 14: Impact of drivers
PART 15: Market challenges
PART 16: Impact of drivers and challenges
PART 17: Market trends
PART 18: Vendor landscape
PART 19: Key vendor analysis
PART 20: Appendix
For more information on this topic, check out the Pharmaceuticals section of the Research and Markets' blog.
For more information about this report visit http://www.researchandmarkets.com/research/sbxj6w/global_metabolic
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-metabolic-disorders-therapeutics-market-to-grow-462-by-2020---increase-in-academia-industry-collaborations-for-drug-development---research-and-markets-300345004.html
SOURCE Research and Markets